Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Granisetron Market

ID: MRFR/HC/35389-HCR
100 Pages
Nidhi Mandole
Last Updated: April 06, 2026

Granisetron Market Research Report By Dosage Form (Oral, Injection, Transdermal), By Application (Chemotherapy-Induced Nausea, Postoperative Nausea, Radiation-Induced Nausea), By End Use (Hospitals, Clinics, Homecare), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Granisetron Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Healthcare, BY Dosage Form (USD Billion)
      1. 4.1.1 Oral
      2. 4.1.2 Injection
      3. 4.1.3 Transdermal
    2. 4.2 Healthcare, BY Application (USD Billion)
      1. 4.2.1 Chemotherapy-Induced Nausea
      2. 4.2.2 Postoperative Nausea
      3. 4.2.3 Radiation-Induced Nausea
    3. 4.3 Healthcare, BY End Use (USD Billion)
      1. 4.3.1 Hospitals
      2. 4.3.2 Clinics
      3. 4.3.3 Homecare
    4. 4.4 Healthcare, BY Distribution Channel (USD Billion)
      1. 4.4.1 Hospital Pharmacies
      2. 4.4.2 Retail Pharmacies
      3. 4.4.3 Online Pharmacies
    5. 4.5 Healthcare, BY Region (USD Billion)
      1. 4.5.1 North America
        1. 4.5.1.1 US
        2. 4.5.1.2 Canada
      2. 4.5.2 Europe
        1. 4.5.2.1 Germany
        2. 4.5.2.2 UK
        3. 4.5.2.3 France
        4. 4.5.2.4 Russia
        5. 4.5.2.5 Italy
        6. 4.5.2.6 Spain
        7. 4.5.2.7 Rest of Europe
      3. 4.5.3 APAC
        1. 4.5.3.1 China
        2. 4.5.3.2 India
        3. 4.5.3.3 Japan
        4. 4.5.3.4 South Korea
        5. 4.5.3.5 Malaysia
        6. 4.5.3.6 Thailand
        7. 4.5.3.7 Indonesia
        8. 4.5.3.8 Rest of APAC
      4. 4.5.4 South America
        1. 4.5.4.1 Brazil
        2. 4.5.4.2 Mexico
        3. 4.5.4.3 Argentina
        4. 4.5.4.4 Rest of South America
      5. 4.5.5 MEA
        1. 4.5.5.1 GCC Countries
        2. 4.5.5.2 South Africa
        3. 4.5.5.3 Rest of MEA
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Healthcare
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Helsinn Healthcare SA (CH)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Teva Pharmaceutical Industries Ltd (IL)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Mylan N.V. (NL)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Sandoz International GmbH (CH)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 AstraZeneca PLC (GB)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Bristol-Myers Squibb Company (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Eisai Co., Ltd. (JP)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Hikma Pharmaceuticals PLC (GB)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Roche Holding AG (CH)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 NORTH AMERICA MARKET ANALYSIS
    3. 6.3 US MARKET ANALYSIS BY DOSAGE FORM
    4. 6.4 US MARKET ANALYSIS BY APPLICATION
    5. 6.5 US MARKET ANALYSIS BY END USE
    6. 6.6 US MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    7. 6.7 CANADA MARKET ANALYSIS BY DOSAGE FORM
    8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
    9. 6.9 CANADA MARKET ANALYSIS BY END USE
    10. 6.10 CANADA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    11. 6.11 EUROPE MARKET ANALYSIS
    12. 6.12 GERMANY MARKET ANALYSIS BY DOSAGE FORM
    13. 6.13 GERMANY MARKET ANALYSIS BY APPLICATION
    14. 6.14 GERMANY MARKET ANALYSIS BY END USE
    15. 6.15 GERMANY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    16. 6.16 UK MARKET ANALYSIS BY DOSAGE FORM
    17. 6.17 UK MARKET ANALYSIS BY APPLICATION
    18. 6.18 UK MARKET ANALYSIS BY END USE
    19. 6.19 UK MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    20. 6.20 FRANCE MARKET ANALYSIS BY DOSAGE FORM
    21. 6.21 FRANCE MARKET ANALYSIS BY APPLICATION
    22. 6.22 FRANCE MARKET ANALYSIS BY END USE
    23. 6.23 FRANCE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    24. 6.24 RUSSIA MARKET ANALYSIS BY DOSAGE FORM
    25. 6.25 RUSSIA MARKET ANALYSIS BY APPLICATION
    26. 6.26 RUSSIA MARKET ANALYSIS BY END USE
    27. 6.27 RUSSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    28. 6.28 ITALY MARKET ANALYSIS BY DOSAGE FORM
    29. 6.29 ITALY MARKET ANALYSIS BY APPLICATION
    30. 6.30 ITALY MARKET ANALYSIS BY END USE
    31. 6.31 ITALY MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    32. 6.32 SPAIN MARKET ANALYSIS BY DOSAGE FORM
    33. 6.33 SPAIN MARKET ANALYSIS BY APPLICATION
    34. 6.34 SPAIN MARKET ANALYSIS BY END USE
    35. 6.35 SPAIN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    36. 6.36 REST OF EUROPE MARKET ANALYSIS BY DOSAGE FORM
    37. 6.37 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
    38. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE
    39. 6.39 REST OF EUROPE MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    40. 6.40 APAC MARKET ANALYSIS
    41. 6.41 CHINA MARKET ANALYSIS BY DOSAGE FORM
    42. 6.42 CHINA MARKET ANALYSIS BY APPLICATION
    43. 6.43 CHINA MARKET ANALYSIS BY END USE
    44. 6.44 CHINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    45. 6.45 INDIA MARKET ANALYSIS BY DOSAGE FORM
    46. 6.46 INDIA MARKET ANALYSIS BY APPLICATION
    47. 6.47 INDIA MARKET ANALYSIS BY END USE
    48. 6.48 INDIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    49. 6.49 JAPAN MARKET ANALYSIS BY DOSAGE FORM
    50. 6.50 JAPAN MARKET ANALYSIS BY APPLICATION
    51. 6.51 JAPAN MARKET ANALYSIS BY END USE
    52. 6.52 JAPAN MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    53. 6.53 SOUTH KOREA MARKET ANALYSIS BY DOSAGE FORM
    54. 6.54 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
    55. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE
    56. 6.56 SOUTH KOREA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    57. 6.57 MALAYSIA MARKET ANALYSIS BY DOSAGE FORM
    58. 6.58 MALAYSIA MARKET ANALYSIS BY APPLICATION
    59. 6.59 MALAYSIA MARKET ANALYSIS BY END USE
    60. 6.60 MALAYSIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    61. 6.61 THAILAND MARKET ANALYSIS BY DOSAGE FORM
    62. 6.62 THAILAND MARKET ANALYSIS BY APPLICATION
    63. 6.63 THAILAND MARKET ANALYSIS BY END USE
    64. 6.64 THAILAND MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    65. 6.65 INDONESIA MARKET ANALYSIS BY DOSAGE FORM
    66. 6.66 INDONESIA MARKET ANALYSIS BY APPLICATION
    67. 6.67 INDONESIA MARKET ANALYSIS BY END USE
    68. 6.68 INDONESIA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    69. 6.69 REST OF APAC MARKET ANALYSIS BY DOSAGE FORM
    70. 6.70 REST OF APAC MARKET ANALYSIS BY APPLICATION
    71. 6.71 REST OF APAC MARKET ANALYSIS BY END USE
    72. 6.72 REST OF APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    73. 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. 6.74 BRAZIL MARKET ANALYSIS BY DOSAGE FORM
    75. 6.75 BRAZIL MARKET ANALYSIS BY APPLICATION
    76. 6.76 BRAZIL MARKET ANALYSIS BY END USE
    77. 6.77 BRAZIL MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    78. 6.78 MEXICO MARKET ANALYSIS BY DOSAGE FORM
    79. 6.79 MEXICO MARKET ANALYSIS BY APPLICATION
    80. 6.80 MEXICO MARKET ANALYSIS BY END USE
    81. 6.81 MEXICO MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    82. 6.82 ARGENTINA MARKET ANALYSIS BY DOSAGE FORM
    83. 6.83 ARGENTINA MARKET ANALYSIS BY APPLICATION
    84. 6.84 ARGENTINA MARKET ANALYSIS BY END USE
    85. 6.85 ARGENTINA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    86. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DOSAGE FORM
    87. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
    88. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE
    89. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    90. 6.90 MEA MARKET ANALYSIS
    91. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DOSAGE FORM
    92. 6.92 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
    93. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE
    94. 6.94 GCC COUNTRIES MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    95. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DOSAGE FORM
    96. 6.96 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
    97. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE
    98. 6.98 SOUTH AFRICA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    99. 6.99 REST OF MEA MARKET ANALYSIS BY DOSAGE FORM
    100. 6.100 REST OF MEA MARKET ANALYSIS BY APPLICATION
    101. 6.101 REST OF MEA MARKET ANALYSIS BY END USE
    102. 6.102 REST OF MEA MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    103. 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. 6.104 RESEARCH PROCESS OF MRFR
    105. 6.105 DRO ANALYSIS OF HEALTHCARE
    106. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. 6.109 HEALTHCARE, BY DOSAGE FORM, 2024 (% SHARE)
    110. 6.110 HEALTHCARE, BY DOSAGE FORM, 2024 TO 2035 (USD Billion)
    111. 6.111 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
    112. 6.112 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
    113. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE)
    114. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
    115. 6.115 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    116. 6.116 HEALTHCARE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Billion)
    117. 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.2.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.2.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.2.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
      1. 7.3.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.3.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.3.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.3.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      1. 7.4.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.4.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.4.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.4.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.5.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.5.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.5.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.5.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.6.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.6.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.6.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.6.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.7.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.7.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.7.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.7.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
      1. 7.8.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.8.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.8.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.8.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      1. 7.9.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.9.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.9.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.9.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      1. 7.10.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.10.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.10.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.10.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      1. 7.11.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.11.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.11.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.11.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      1. 7.12.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.12.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.12.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.12.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.13.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.13.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.13.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.13.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
      1. 7.14.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.14.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.14.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.14.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
      1. 7.15.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.15.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.15.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.15.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      1. 7.16.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.16.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.16.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.16.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      1. 7.17.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.17.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.17.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.17.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      1. 7.18.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.18.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.18.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.18.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      1. 7.19.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.19.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.19.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.19.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      1. 7.20.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.20.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.20.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.20.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.21.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.21.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.21.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.21.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.22.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.22.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.22.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.22.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      1. 7.23.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.23.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.23.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.23.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      1. 7.24.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.24.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.24.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.24.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      1. 7.25.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.25.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.25.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.25.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      1. 7.26.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.26.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.26.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.26.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.27.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.27.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.27.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.27.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      1. 7.28.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.28.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.28.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.28.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      1. 7.29.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.29.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.29.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.29.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      1. 7.30.1 BY DOSAGE FORM, 2025-2035 (USD Billion)
      2. 7.30.2 BY APPLICATION, 2025-2035 (USD Billion)
      3. 7.30.3 BY END USE, 2025-2035 (USD Billion)
      4. 7.30.4 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Billion)
    30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.31.1
    1. 7.32 ACQUISITION/PARTNERSHIP
  10. 7.32.1

Healthcare Market Segmentation

Healthcare By Dosage Form (USD Billion, 2025-2035)

  • Oral
  • Injection
  • Transdermal

Healthcare By Application (USD Billion, 2025-2035)

  • Chemotherapy-Induced Nausea
  • Postoperative Nausea
  • Radiation-Induced Nausea

Healthcare By End Use (USD Billion, 2025-2035)

  • Hospitals
  • Clinics
  • Homecare

Healthcare By Distribution Channel (USD Billion, 2025-2035)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions